
Hims & Hers (HIMS) shares tanked more than 30% on Monday after pharmaceutical behemoth Novo Nordisk (NVO) terminated its distribution agreement with the telehealth company.
Novo Nordisk agreed to a high-profile partnership with HIMS to distribute Wegovy, its blockbuster weight-loss treatment.